Pallasite Ventures
VC Fund
Chicago, United States
Pallasite Ventures is a VC fund in Chicago focused on Software and Health Care. Pallasite Ventures provides early-stage financing for high-growth companies across a variety of industries. It was founded by David Light and is based in Chicago, Illinois.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 26%
Last updated:
For AI agents: llms.txt
Industries Pallasite Ventures invests in
SoftwareHealth CareBiotechnologyMobileSaaS
Stages Pallasite Ventures invests in
SeedSeries ASeries BSeries CVenture - Series Unknown
Countries Pallasite Ventures invests in
CanadaUnited States
Round sizes
Seed $750k–$5MSeries A $3.2M–$20MSeries B $14M–$115M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $750k–$5M
- Series A
- $3.2M–$20M
- Series B
- $14M–$115M
Investment Focus
Industry
- Software 6 (16%)
- Health Care 6 (16%)
- Biotechnology 5 (13%)
- Mobile 4 (11%)
- SaaS 3 (8%)
Stage
- Seed 16 (42%)
- Series A 7 (18%)
- Series B 2 (5%)
- Series C 2 (5%)
- Venture - Series Unknown 2 (5%)
Country
- Canada 12 (32%)
- United States 12 (32%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christopher Bissonnette
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Christopher Bissonnette
Managing Partner
|
Managing Partner | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M / Series B / Jan 08, 2025 | ||
| Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $20M / Series A / Dec 05, 2023 | ||
| Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M / Seed / Jul 21, 2022 | ||
| Zeno Power is a company that creates advanced power systems that use radioisotopes. The company intends to increase the production of small-scale nuclear batteries capable of powering spacecraft and undersea technologies for years.Zeno, founded in 2018 by three Vanderbilt University students, intends to be the first to enter the commercial marketwith a novel new combination of affordability and lightweight. | $20M / Series A / Apr 26, 2022 | ||
| Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $14.9M / Series A / Jan 19, 2022 | ||
| Prescryptive Health is a digital health company focused on improving the prescription drug market | $26M / Series A / Aug 25, 2020 | ||
| Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $20M / Series A / Jan 09, 2020 | ||
| Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $3M / Seed / Dec 17, 2019 | ||
| Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first- and best-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech,Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026 treating women with metastatic breast cancer. A Phase 1b mono-therapy trial in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States has also been completed with results providing further evidence of the benefit of inhibiting RSK in breast cancer. A phase 2a trial in HR+/HER2- metastatic breast cancer is currently underway at a number of leading academic research hospitals. RSK inhibition has also been proven to provide benefits in multiple hematologic cancers in the hematologic malignancies space as well. | $5M / Seed / Nov 20, 2019 | ||
| CTO.ai is a serverless infrastructure designed for the needs of fast moving development teams who want to measure what the business cares about. Our Commands, Pipelines, Services and Insights provide all of the tools you need to easily integrate your GitOps and ChatOps workflows, so that you can workflow smarter, not harder. | $7.5M / Seed / Nov 04, 2019 | ||
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
SaaS Investors
117,441 investors
Software Investors
57,331 investors
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Mobile Investors
15,046 investors
SaaS VC Funds
71,923 investors
Software VC Funds
36,593 investors
Health Care VC Funds
36,465 investors
FAQ
What does Pallasite Ventures invest in?
Pallasite Ventures invests primarily in Software, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 38 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pallasite Ventures's check size?
Pallasite Ventures typically joins rounds of $750k–$5M at Seed, $3.2M–$20M at Series A and $14M–$115M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pallasite Ventures participates in.
How do I contact Pallasite Ventures?
Public channels for Pallasite Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pallasite Ventures?
The team at Pallasite Ventures includes Christopher Bissonnette (Managing Partner) and Christopher Bissonnette (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
